Back to Search Start Over

The circulating soluble form of the CD40 costimulatory immune checkpoint receptor and liver metastasis risk in rectal cancer.

The circulating soluble form of the CD40 costimulatory immune checkpoint receptor and liver metastasis risk in rectal cancer.

Authors :
Meltzer, Sebastian
Torgunrud, Annette
Abrahamsson, Hanna
Solbakken, Arne Mide
Flatmark, Kjersti
Dueland, Svein
Bakke, Kine Mari
Bousquet, Paula Anna
Negård, Anne
Johansen, Christin
Lyckander, Lars Gustav
Larsen, Finn Ole
Schou, Jakob Vasehus
Redalen, Kathrine Røe
Ree, Anne Hansen
Source :
British Journal of Cancer; Jul2021, Vol. 125 Issue 2, p240-246, 7p
Publication Year :
2021

Abstract

<bold>Background: </bold>In colorectal cancer, the inflamed tumour microenvironment with its angiogenic activities is immune- tolerant and incites progression to liver metastasis. We hypothesised that angiogenic and inflammatory factors in serum samples from patients with non-metastatic rectal cancer could inform on liver metastasis risk.<bold>Methods: </bold>We measured 84 angiogenic and inflammatory markers in serum sampled at the time of diagnosis within the population-based cohort of 122 stage I-III patients. In a stepwise manner, the statistically strongest proteins associated with time to development of liver metastasis were analysed in the corresponding serum samples from 273 stage II-III rectal cancer patients in three independent cohorts.<bold>Results: </bold>We identified the soluble form of the costimulatory immune checkpoint receptor cluster of differentiation molecule 40 (sCD40) as a marker of liver metastasis risk across all patient cohorts-the higher the sCD40 level, the shorter time to liver metastasis. In patients receiving neoadjuvant treatment, the sCD40 value remained an independent variable associated with progression to liver metastasis along with the local treatment response. Of note, serum sCD40 was not associated with progression to lung metastasis.<bold>Conclusions: </bold>Circulating sCD40 is a marker of liver metastasis risk in rectal cancer and may be developed for use in clinical practice. [ABSTRACT FROM AUTHOR]

Details

Language :
English
ISSN :
00070920
Volume :
125
Issue :
2
Database :
Complementary Index
Journal :
British Journal of Cancer
Publication Type :
Academic Journal
Accession number :
151489961
Full Text :
https://doi.org/10.1038/s41416-021-01377-y